Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
343
resultados
Última actualización
03/08/2026 [08:30:00]
Resultados 200 a 225 de 343
Resumen de: CN122282992A
本发明提供了一种测定人血浆中β‑淀粉样蛋白42/40比率的质谱方法，包括采用¹5N稳定同位素标记的完整Aβ42和Aβ40蛋白作为内标，通过免疫沉淀技术对血浆样本进行提取与纯化，并利用Lys‑N蛋白酶解产生特征性肽段，最终通过液相色谱‑串联质谱进行靶向定量分析。Aβ42的特征肽段是Aβ28‑42 KGAIIGLMVGGVVIA；Aβ40的特征肽段是Aβ28‑40 KGAIIGLMVGGVV。相较于完整蛋白，本发明中的特征肽段不易发生聚集且在质谱中具有更高的电离效率，展现出优异的特异性、重复性与灵敏度，能够为阿尔茨海默症的诊断提供可靠依据。
Resumen de: WO2026135697A1
Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Resumen de: WO2022118944A1
The present invention addresses the problem of providing: a method for evaluating dementia; and a composition for preventing or treating deterioration in brain function, or maintaining or improving brain function. The intestinal microflora of healthy people, people with mild cognitive impairment, or patients suffering from Alzheimer's disease were compared. As a result, a microorganism belonging to the genus Faecalibacterium was selected as an intestinal microorganism associated with cognitive function. Furthermore, it has been found that Faecalibacterium prausnitzii having a specific DNA exhibits an effect of ameliorating brain function deterioration such as learning and memory impairment.
Resumen de: WO2026132413A1
The present invention relates to an antibody or antigen-binding fragment thereof, which binds to TDP-43, i.e. TAR DNA-binding protein 43, and to therapeutic and diagnostic uses thereof.
Resumen de: WO2026132444A1
The present invention relates to in vitro methods for diagnosing or prognosing diseases and disorders associated with altered orexin-A levels. It further relates to in vitro methods for monitoring the effect of a treatment or the evolution of a disease or disorder associated with altered orexin-A levels. It also relates to the use of orexin-A fragment as biomarker for the in vitro diagnosis of diseases and disorders associated with altered orexin-A levels.
Resumen de: DE102024139461A1
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines In-vitro-Modells für eine neurologische Erkrankung des Menschen. Darüber hinaus betrifft die Erfindung das gemäß dem hierin offenbarten erfindungsgemäßen Verfahren hergestellte In-vitro-Modell. Außerdem betrifft die Erfindung die Verwendung des In-vitro-Modells der Erfindung bei Arzneimitteltests. Darüber hinaus betrifft die Erfindung Verfahren zum Testen der Wirksamkeit von Arzneimitteln bei der Vorbeugung, Verzögerung und Linderung einer neurologischen Erkrankung des Menschen.
Resumen de: WO2026134539A1
The present invention relates to a DNA aptamer specifically binding to an alpha-synuclein protein and uses thereof. Specifically, the present invention relates to a DNA aptamer selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1 to 12 and binding specifically to an α-synuclein protein, and a composition for detecting an α-synuclein protein, a detection kit, a detection chip or a microarray, all comprising the aptamer as an active ingredient. In addition, the present invention relates to a method for detecting an α-synuclein protein, a method for providing information for diagnosing a degenerative brain disease, a composition for diagnosing a degenerative brain disease, and a pharmaceutical composition for preventing or treating a neurodegenerative disease, all using the DNA aptamer of the present invention.
Resumen de: WO2026134051A1
This plasmalogen detection method comprises: a sample preparation step for mixing a Schiff's reagent and a specimen containing a plasmalogen to obtain a sample; a reaction step for reacting the plasmalogen in the sample with the Schiff's reagent; and a contact step for bringing at least some of the sample reacted in the reaction step into contact with a stationary phase containing a silica gel.
Resumen de: WO2026132535A1
The invention relates to an in vitro method for the differential diagnosis and/or prognosis of the presence or absence of a central nervous system (CNS) inflammation, in a subject with one or more symptoms of an acute neurological syndrome, said diagnosis and/or prognosis comprising: i) a CNS infection or ii) a neurological disorder without a CNS infection, or iii) an exclusion of i) and ii). The invention further relates to an in vitro method for detecting proadrenomedullin (proADM) or fragment(s) thereof in a cerebrospinal fluid sample. The invention further relates to kits for carrying out the methods of the invention.
Resumen de: WO2026132195A1
The present invention concerns the field of diagnostics. In particular, it relates to a method for analyzing a protein analyte in a heparin-treated sample comprising or suspected to comprise said protein analyte, said method comprising the step of contacting said heparin-treated sample with spermidine prior to analyzing the said protein analyte in the said sample. Moreover, contemplated are a method for assessing a cardiovascular disease or disorder, a neurological disease or disorder, a metabolic disease or disorder or cancer as well as kits and reagent compositions comprising spermidine to be used in the said methods.
Resumen de: US20260177568A1
The present invention provides lateral flow assay devices and methods for detecting nicotinic acetylcholine receptor ligands in liquid samples. The device comprises a porous strip with multiple zones, including a sample deposition zone, a test visualization zone containing an immobilized nicotine conjugate, a control zone, and an absorbent zone. A recombinant acetylcholine receptor protein serves as a mobile agent, either pre-deposited on the strip or added to the sample. The recombinant protein comprises a ligand-binding domain of a nicotinic acetylcholine receptor conjugated to a visually-detectable reporter forming a receptor-reporter conjugate. When nicotinic acetylcholine receptor ligands are present in the sample, they competitively bind to the recombinant receptor protein, reducing binding to the immobilized nicotine conjugate and producing a visually detectable signal inversely proportional to ligand concentration. The invention provides rapid, simple, and field-deployable detection of receptor ligands in environmental samples, including cyanobacterial neurotoxins in surface waters, and biological samples for pharmacological and toxicological applications.
Resumen de: DE102024139033A1
Die Erfindung betrifft ein Peptid, umfassend eine Aminosäuresequenz X6X7X8X9X10X11X12gemäß SEQ ID NO: 1, oder dessen pharmakologisch akzeptable Salze, Derivate und/oder Konjugate, wobei X6ist G oder A, X7ist R oder A, X8ist R oder A, X9ist T oder A, X10ist R oder A, X11ist L oder A, X12ist C oder A, mit der Maßgabe, dass eine der Aminosäuren an Position X6, X7, X8, X9, X10, X11oder X12Alanin sein kann, wobei das Peptid eine Gesamtlänge im Bereich von 7 bis 30 Aminosäuren aufweist, und wobei ein Peptid bestehend aus der Aminosäuresequenz KRRPAKAWSGRRTRLCC gemäß SEQ ID NO: 2 ausgenommen ist. Die Erfindung betrifft ferner Arzneimittel umfassend ein Peptid gemäß SEQ ID NO: 1 sowie eine Verwendung zur Herstellung eines Arzneimittels.
Resumen de: US20260177566A1
The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.
Resumen de: WO2026136613A1
The present invention relates to methods for treating an ophthalmic condition in a defined patient in need of treatment thereof. The methods comprise inducing the activity of peroxisome proliferator–activated receptor gamma coactivator-1 alpha (PGC1α) in a defined patient that needs treatment of an ophthalmic condition. The defined patient in these methods has been previously identified as having reduced carboxylesterase 1 (CES1) activity, compared to normal activity levels of CES1.
Resumen de: AU2024406255A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: US20260177567A1
The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.
Resumen de: US20260177555A1
0000 The present disclosure relates to a method of separating, purifying, detecting, measuring, or analyzing a sample using a liquid chromatography.
Resumen de: WO2026134722A1
The present invention relates to a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane as an active ingredient and use thereof. More specifically, the present invention relates to: a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient; and use thereof, for example, a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition, as a composition for preventing, treating or ameliorating diseases requiring the oxidative inactivation of PTEN, and a method for detecting PTEN redox state.
Resumen de: US20260177544A1
An object of the present invention is to provide a highly sensitive method for detecting a biomarker. The object can be achieved by a method for detecting a test substance in a specimen of the present invention, the method being (A) a sandwich method including: (1) bringing a specimen into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-test substance complex of the primary substance and a test substance in the specimen; (2) bringing the primary substance-test substance complex into contact with a secondary substance, to form a primary substance-test substance-secondary substance complex of the primary substance-test substance complex and the secondary substance; and (3) detecting the primary substance-test substance-secondary substance complex on the magnetic particle with a laser; or (B) a competitive method including: (1) bringing a specimen and a secondary substance into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-secondary substance complex of the primary substance and the secondary substance; and (2) detecting the primary substance-secondary substance complex on the magnetic particle with a laser.
Resumen de: US20260176315A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target IL-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent.
Resumen de: US20260177562A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.
Resumen de: US20260176652A1
0000 In certain embodiments the present invention provides a method of treating hearing loss comprising: (a) administering a gene suppression agent that suppresses both copies of an endogenous gene causing the hearing loss; and (b) administering an exogenous wild-type allele engineered to resist suppression by the gene suppression agent. 0000 The present invention provides in certain embodiments a method of treating a genetic hearing loss (GHL) in a patient in need thereof comprising: (a) identifying a mutation in a GHL-causing gene, wherein the mutation causes GHL in the patient; and (b) administering to the patient a pharmaceutical composition comprising a therapeutic miRNA and a pharmaceutically acceptable carrier, wherein the GHL therapeutic miRNA is of 18 to 25 nucleotides in length and knocks-down the GHL-causing gene function at a higher level than it knocks-down gene function in a corresponding wild-type gene.
Resumen de: US20260177560A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Resumen de: US20260176364A1
0000 The invention relates to compositions and methods for producing and using antibodies against the alpha7 nicotinic acetylcholine receptor.
Nº publicación: US20260177546A1 25/06/2026
Solicitante:
THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN [US]
The United States of America, as represented by the Secretary, Department of Health and Human
Resumen de: US20260177546A1
The invention provides a method for predicting the susceptibility of a patient suffering from a cancer or a myeloid-mediated disease to immunotherapy. Furthermore, the invention provides a method for treating a patient suffering from a cancer or a myeloid-mediated disease with immunotherapy. In accordance with these embodiments, the inventive method includes assaying myeloid cells obtained from the patient prior to treatment for the expression of CXCR3. The invention also provides a genetically engineered myeloid cell (GEMy) in which the expression of CXCR3 is modulated (up- or down-regulated). The invention further provides a composition comprising the inventive GEMy and a pharmaceutically acceptable carrier. The invention also provides a method for treating a patient in need of immunotherapy comprising administering the inventive composition to a patient.
BOPI
Sede Electrónica
